Oslo, Norway, 25 August 2020.
Successful share issue
Genetic Analysis AS announces the successful private placement of NOK 34.3 million. The issue was oversubscribed and completed in two tranches; the first tranche closed on June 19th was aimed at existing shareholders and at new Norwegian investors, the second tranche closed on August 6th 2020 was aimed at Swedish Medtech investors. In total, NOK 16.0 million were received from existing shareholders and NOK 18.3 million from new investors.
“We have raised the capital to work on the plans to grow the business. We have spent several years developing the technology and have now launched products and received good feedback from the market. Now we will rig for growth and list the company on the stock exchange Merkur or First North during the year.” commented Ronny Hermansen, CEO.
“In connection with the stock exchange listing, we will raise more further capital – from NOK 50 to 100 million, says Hermansen who adds that the amount will be set in collaboration with facilitators. We hope to become more visible as we are a world leader in mapping the gastrointestinal flora.”
GA strengthen its management team
Genetic Analysis AS announces that Mr. Tore Grøttum has been appointed interim Chief Financial Officer with immediate effect. Mr. Tore Grøttum has a broad CFO experience from multiple industries and long experience with listed companies ensuring correct handling of requirements imposed by different stakeholders.
For any questions, please contact, Ronny Hermansen, CEO, firstname.lastname@example.org
Comments are closed.